Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
• • D—TEXTILES; PAPER
  • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
  • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
  • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
  • D06M13/50—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with organometallic compounds; with organic compounds containing boron, silicon, selenium or tellurium atoms
  • D06M13/51—Compounds with at least one carbon-metal or carbon-boron, carbon-silicon, carbon-selenium, or carbon-tellurium bond
  • D06M13/513—Compounds with at least one carbon-metal or carbon-boron, carbon-silicon, carbon-selenium, or carbon-tellurium bond with at least one carbon-silicon bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6953—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a fibre, a textile, a slab or a sheet
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5115—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5192—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0061—Use of materials characterised by their function or physical properties
  • A61L26/0066—Medicaments; Biocides
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/62227—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres
  • C04B35/62231—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres based on oxide ceramics
  • C04B35/6224—Fibres based on silica
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
  • C04B35/628—Coating the powders or the macroscopic reinforcing agents
  • C04B35/62844—Coating fibres
• • D—TEXTILES; PAPER
  • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
  • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
  • D01D5/00—Formation of filaments, threads, or the like
  • D01D5/0007—Electro-spinning
  • D01D5/0015—Electro-spinning characterised by the initial state of the material
  • D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
• • D—TEXTILES; PAPER
  • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
  • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
  • D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
  • D01F9/08—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
• • D—TEXTILES; PAPER
  • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
  • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
  • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
  • D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
  • D06M13/402—Amides imides, sulfamic acids
  • D06M13/415—Amides of aromatic carboxylic acids; Acylated aromatic amines
• • D—TEXTILES; PAPER
  • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
  • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
  • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
  • D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
  • D06M13/402—Amides imides, sulfamic acids
  • D06M13/418—Cyclic amides, e.g. lactams; Amides of oxalic acid
• • D—TEXTILES; PAPER
  • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
  • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
  • D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
  • D06M16/003—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/30—Constituents and secondary phases not being of a fibrous nature
  • C04B2235/44—Metal salt constituents or additives chosen for the nature of the anions, e.g. hydrides or acetylacetonate
  • C04B2235/441—Alkoxides, e.g. methoxide, tert-butoxide
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/50—Constituents or additives of the starting mixture chosen for their shape or used because of their shape or their physical appearance
  • C04B2235/52—Constituents or additives characterised by their shapes
  • C04B2235/5208—Fibers
  • C04B2235/5264—Fibers characterised by the diameter of the fibers
• • D—TEXTILES; PAPER
  • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
  • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
  • D06M2400/00—Specific information on the treatment or the process itself not provided in D06M23/00-D06M23/18
  • D06M2400/01—Creating covalent bondings between the treating agent and the fibre
• • D—TEXTILES; PAPER
  • D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
  • D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
  • D10B2101/00—Inorganic fibres
  • D10B2101/02—Inorganic fibres based on oxides or oxide ceramics, e.g. silicates

Definitions

• the invention concerns a nanofiber structure with immobilized organic substance.
• the invention also concerns a method of preparation of the nanofiber structure with immobilized organic substance.
• the employed organic substance usually cannot be recovered from the application area, e.g. for further use, and a new quantity of the functional organic substance needs to be added into the next production batch. This, however, significantly increases costs and the reaction product contains free enzyme which is not desirable from the viewpoint of further product use.
• the quantity of the immobilized substance depends on the number of suitable bonding places for immobilization and on the specific surface of the substrate. From this point of view nanofibers are a particularly suitable substrate because their specific surface is in units to tens of m 2 /g while they keep suitable mechanical properties; those properties make it possible to form shapeable nanofiber layers that may be easily placed into a wound or into a holder in a biochemical reactor and after completion of the application they may be removed.
• patents CZ 294274 or WO 2005024101 describe a method of nanofiber preparation by electrostatic spinning. However, the patents CZ 294274 or WO 2005024101, do not specify in detail polymer solutions for preparation of the nanofibers.
• methyltrimethoxysilane is used as a precursor to prepare silica nanofibers.
• the nanofibers will have hydrophobic properties as a result of presence of methyl groups on the surface and the number of Si—OH groups on the surface for its subsequent potential modification with aminoalkylalkoxysilane will be low. For this reason the procedure under WO 2009018104 is not suitable for preparation of initial silica nanofibers for the subsequent stages of modification and immobilization of organic substance.
• JP20040041335, JP20040161234 and JP20040243580 describe preparation of an organic-inorganic nanofiber composite made of a regular framework of polyethylene imide fibers with layers of silicon dioxide applied with a sol-gel method.
• the resulting composite material is intended to trap, or to increase concentrations of, various substances in the prepared structure, however, only as a filter, i.e. in gaps between individual nanofibers, or by simple adsorption of the desired particles in the bulk nanofiber composite.
• the packaging paper under the patent KR20090058155 is made of nanofibers obtained by electrostatic spinning of a biodegradable organic polymer with addition of sol of silicon dioxide and silver nitrate.
• the resulting product has antiseptic and antibacterial properties but it is not suitable for immobilization of organic substance.
• the patent KR20100058372 describes preparation of a catalyst from mesoporous nanofibers of silicon dioxide prepared by growing from a gaseous phase and subsequent introduction of a catalyst with silane on the surface and into the pores of the nanofibers prepared in this manner.
• the resulting product is described as a catalyst of various organic reactions and it is not used for immobilization of organic substance.
• the drawback of the existing state of technology consists in the absence of a sufficiently biochemically stable structure capable of sufficiently high, efficient and, in terms of time, stable immobilization of organic substance.
• the objective of this invention is to eliminate, or at least to minimize, disadvantages of the current state of technology.
• the objective of the invention is achieved by a nanofiber structure with immobilized organic substance, the principle of which consists in the fact that silica nanofibers have their surface modified by a reaction with aminoalkylalkoxysilane and subsequently organic substance is immobilized on their surface with peptide or hydrogen bonds.
• Silica nanofibers are suitable particularly thanks to their high stability in biochemical reactions and thanks to their dissolving ability in body fluids.
• the dissolving rate of silica nanofibers is controlled by the temperature of thermal processing of the silica nanofibers and therefore the nanofibers may be removed from the wound along with the immobilized substance after a previously specified time and the residues of silica nanofibers potentially released in the place of application, in a wound or bioreactor, e.g. by breaking etc., are then dissolved in body fluids or in the bioreactor sufficiently quickly without any negative side effects.
• Silica nanofibers have another advantage that their surface with high numbers of Si—OH groups can be easily modified with reactions in which Si—OH groups are linked via covalent bonds with aminoalkylalkoxysilanes whose amino groups subsequently enable formation of relatively strong peptide bonds or slightly weaker hydrogen bonds with the immobilized organic substance.
• the principle of the method of preparation of the nanofiber structure with immobilized organic substance consist in preparation of an initial sol from tetraalkoxysilane using a sol-gel method and the sol is then exposed to electrostatic spinning; the resulting nanofiber structure is heat-treated and its surface is treated with aminoalkylalkoxysilane; the surface of the nanofiber structure is then exposed to a solution organic substance and the organic substance is immobilized by means of peptide or hydrogen bonds on the surface of the nanofiber structure.
• the basis of this method is to create a nanofiber structure, e.g. in form of silica nanofibers made by electrostatic spinning from a sol prepared by a sol-gel method from tetraalkoxysilane using acidic catalysis and without additional organic polymers.
• This method can be used to prepare silica nanofibers with the average diameter in the range 100 to 1000 nm (depending on the conditions of preparation of the initial sol and the conditions of electrostatic spinning) to form a nanofiber structure (layer) that can be directly used for subsequent operations, without the necessity to remove any additives by heat treatment at high temperatures.
• Specific surfaces of nanofiber structures (layers) prepared in this manner range from units to tens of m 2 /g and thus they ensure large surfaces for immobilization of organic substance even if the nanofiber layer is thin.
• the resulting properties of the nanofiber structure e.g. the number of active Si—OH groups for subsequent bonds with aminoalkylalkoxysilane and chemical durability against water and body fluids, are fundamentally affected by a sufficient heat treatment of the nanofiber layer before immobilization of organic substance.
• the morphology of nanofibers practically does not change up to the temperature around 850° C., when it transforms into silica glass (except a slight reduction of their diameters as a result of their thickened structure at high temperatures).
• silica nanofibers gradually reduce their chemical solubility and the number of active Si—OH groups for subsequent bonds with aminoalkylalkoxysilane.
• the surface of nanofibers is therefore modified by a solution of aminoalkylalkoxysilane which forms covalent bonds, by polycondensation via alkoxy groups, with surface Si—OH groups of silica nanofibers and with its free aminoalkyl group provides a primary functional amino group for the formation of peptide or hydrogen bonds with organic substance.
• a suitable solvent or environment water, alcohol or other organic solution
• the immobilization of organic substance on the surface of silica nanofibers with the surface modified according to this invention is sufficiently strong to ensure that during the subsequent application of the nanofiber structure with immobilized organic substance, e.g.
• the immobilized organic substance operates but it is not released from the nanofiber structure or is released only in small quantities, i.e. only in minimum quantities This ensures a long-term, contact and high concentration of organic substance at a place of their desired application, without being washed away and without excessive release from the place of application.
• the prepared sol was used for electrostatic spinning at the voltage of 50 kV and the distance of 15 cm.
• the average size of the prepared nanofibers was 180 nm.
• the resulting nanofiber structure in from of a layer of nanofibers was heat-treated at 180° C. for 2 hours in a drying kiln and the surface of silica nanofibers was modified by immersion into a 2% solution of 3-aminopropyltriethoxysilane in anhydrous ethanol for 1 hour at the laboratory temperature.
• the modified nanofiber structure was washed three times with anhydrous ethanol and submerged into 2% solution of tetracycline or penicillin in anhydrous ethanol for 2 hours at the laboratory temperature.
• the nanofiber structure with the immobilized antibiotic (organic substance) was flushed twice with anhydrous ethanol and left to dry in a desiccator.
• the function of the nanofiber structure with the immobilized antibiotic was verified by antibacterial tests on a selected group of pathogenic bacterial strains that may cause problems particularly in dermatology. They included bacterial strains Staphylococcus aureus, MRSA, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Proteus mirabilis and Pseudomonas aeruginosa. Samples of the nanofiber structure with the immobilized antibiotic were placed into a center of a Petri dish with respective bacterial inoculum of a selected bacterial strain. The samples were incubated in a thermostat for 24 hours at 37° C. Further, the size of the so-called halo zones was evaluated (i.e. zones around the nanofiber structure with immobilized antibiotics).
• the prepared sol was used for electrostatic spinning at the voltage of 50 kV and the distance of 15 cm.
• the average size of the prepared nanofibers was 580 nm.
• the resulting nanofiber structure was in from of a layer of nanofibers was heat-treated at 180° C. for 2 hours in a drying kiln and the surface of nanofibers was subsequently modified with a 2% solution of 3-aminopropyltrimethoxysilane in distilled water for 1 hour at the laboratory temperature.
• the immobilization of the enzymes on the nanofiber structure was verified with a histochemical azocopulation reaction of alpha-naphtyl acetate and chromogenic dye with the enzyme.
• the solution of alpha-naphtyl acetate and Fast Blue BB dye in phosphate buffer in combination with the enzyme formed colored deposits of immobilized enzyme that were visible in a microscope and demonstrated its presence.
• the tests were performed as comparative against a nanofiber structure made of silica nanofibers on which no enzyme was immobilized hereunder, while no deposits as described above were found on the control nanofiber structure without the enzymes.

Landscapes

• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Inorganic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Ceramic Engineering (AREA)
• Medicinal Chemistry (AREA)
• Manufacturing & Machinery (AREA)
• Materials Engineering (AREA)
• Textile Engineering (AREA)
• Organic Chemistry (AREA)
• Structural Engineering (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Dispersion Chemistry (AREA)
• Mechanical Engineering (AREA)
• Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
• Silicon Compounds (AREA)
• Chemical Or Physical Treatment Of Fibers (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=47605254

Family Applications (1)

Country Status (4)

Cited By (5)

Families Citing this family (4)

Family Cites Families (9)

• 2012
  • 2012-08-14 CZ CZ20120549A patent/CZ303911B6/cs not_active IP Right Cessation
  • 2012-12-10 EP EP12818872.9A patent/EP2884968A1/en not_active Withdrawn
  • 2012-12-10 US US14/421,256 patent/US20150240411A1/en not_active Abandoned
  • 2012-12-10 WO PCT/CZ2012/000128 patent/WO2014026656A1/en active Application Filing

Also Published As

Similar Documents

Legal Events